Type 2 diabetes mellitus (T2DM) often requires pharmacological management, with newer agents like glucagon-like peptide-1 (GLP-1) receptor agonists (GLP-1 RA) and dual gastric inhibitory polypeptide (GIP)/GLP-1 receptor agonists offering metabolic and cardiovascular benefits. The gene discussed is GLP1R; the disease is type 2 diabetes mellitus.